Regulation - Merck & Co, Neurological


Current filters:

Merck & CoNeurological

Popular Filters

New Zealand views access to sugammadex and atomoxetine and baclofen injection funding


New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on the following proposals…

Asia-PacificBridionEli LillyLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalRegulationStrattera

US FDA delays Merck & Co's insomnia drug suvorexant, issuing CRL


There was disappointment for US drug giant Merck & Co (NYSE: MRK), which said that it has received a…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationsuvorexant

US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses


The US Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationsuvorexant

Briefs: Glenmark challenges Bayer patent; FDA delays Merck & Co's sugammadex


Indian drugmaker Glenmark Generics confirms that it seeking US Food and Drug Administration approval…

BayerBridionDermatologicalsFinacea GelGenericsGlenmark PharmaceuticalsMerck & CoNeurologicalNorth AmericaPatentsPharmaceuticalRegulationsugammadex

New Zealand considers listing Merck & Co's Bridion


New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list the…

Asia-PacificBridionFinancialMerck & CoNeurologicalPharmaceuticalRegulation

EMA Pharmacovigilance committee calls for Tredaptive suspension; contraceptives update


At meetings held last week, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee…

Cardio-vascularEuropeMerck & CoNeurologicalPharmaceuticalRegulationReproductivetetrazepamTredaptive

FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg


US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's…

DegludecDiabetesMerck & CoNeurologicalNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegsuvorexantTresiba

Merck & Co confirms NDA filing for suvorexant in 2012


US drugs giant Merck & Co (NYSE: MRK) yesterday provided an update on the development program for suvorexant,…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationResearchsuvorexant

Merck & Co highlights pipeline progress; plans eight US filings in 2012-


US pharma giant Merck & Co (NYSE:MRK) hosted an upbeat R&D and Business Briefing yesterday, where it…

Anti-Arthritics/RheumaticsBridonCardio-vascularFinancialMerck & CoNeurologicalodanacatibOncologyPharmaceuticalRegulationResearchsuvorexantTredaptive

Company Spotlight



Back to top